As a pharmacist, Ann Gils obtained in 1993 her PhD in Pharmaceutical Sciences. Since 2006 she is Professor at the Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium. The core technology of the laboratory is the development of monoclonal antibodies and antibody fragments with the aim to develop these antibodies either as therapeutics or as diagnostics.
In the past few years, she has developed a number of assays to measure the serum concentrations of TNF inhibitors (infliximab (Remicade, Remsima, Inflectra); adalimumab (Humira); etanercept (Enbrel), golimumab (Simponi)) and anti-drug antibodies. These assays are used to perform Therapeutic Drug Monitoring and to study pharmacokinetics of TNF inhibitor biologicals in different patient groups. She has published more than 150 papers in the field of thrombosis and therapeutic drug monitoring of biologicals.
More info on https://pharm.kuleuven.be/biotech/